CXCR2CXCR2 as a biomarker and therapeutic target of basal type breast cancer

• Main Authors: KANG JAE HYEOK, LEE MIN JAE, LEE SU JAE
• Format: Patent
• Language: English; Korean
• Published: 08.03.2023
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; PHYSICS; PROCESSES OF PREPARING SUCH COMPOSITIONS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; TESTING; VINEGAR; WINE

The present invention relates to a kit for diagnosing a basal-type breast cancer and a method for diagnosing a basal-type breast cancer, wherein the kit measures the expression level of C-X-C Motif Chemokine Receptor 2 (CXCR2) in a sample derived from a breast cancer. In addition, the present invention relates to a pharmaceutical composition for treating a basal-type breast cancer containing a substance that inhibits the expression or activity of CXCR2 or a pharmaceutical composition for inhibiting epithelial-to-mesenchymal transition (EMT) and/or angiogenesis of breast cancer cells. 본 발명은 유방암 유래의 시료 중 CXCR2(C-X-C Motif Chemokine Receptor 2)의 발현 수준을 측정하는 것을 포함하는 기저형(basal type) 유방암 진단용 키트 및 기저형 유방암의 진단방법에 관한 것이다. 또한 본 발명은 CXCR2의 발현 또는 활성을 억제하는 물질을 포함하는 기저형 유방암 치료용 약제학적 조성물 또는 유방암 세포의 상피간엽이행(epithelial-to-mesenchymal transition, EMT) 및/또는 혈관신생 억제용 약제학적 조성물에 관한 것이다.